Novo Nordisk reported a modest rise in revenues last quarter, yet warned that price pressure is tightening margins as the obesity drug market grows crowded. The Danish firm noted that sales growth slowed to 3% from 5% in the previous year, reflecting tougher competition.

The company’s flagship obesity drug, Ozempic, faces new entrants like Eli Lilly’s Mounjaro and Pfizer’s Glyxol. With each launch, Novo must defend its market share, potentially trimming pricing or accelerating innovation to maintain profitability amid a shifting competitive landscape for.

Investors will watch quarterly guidance for signs of a strategic pivot, such as increased R&D spend or pricing adjustments. Analysts suggest that sustained price erosion could erode Novo’s 30% share of the global obesity market, prompting a reassessment of its growth trajectory.

Regulators in the EU and US may scrutinize pricing strategies as competition intensifies, potentially tightening reimbursement frameworks. Novo’s response will shape the broader pharma pricing debate, influencing how companies balance innovation incentives with affordability demands for patients and shareholders globally.